AAIC 2025 Abstract
Determining eligibility for anti‐amyloid treatments using blood biomarkers
By Suzanne Elizabeth Schindler, Anna Hofmann, Madeline Paczynski, Show 4 more authorsBarbara Joy Snider
Study in peopleBiomarkers
Abstract
Background: The Washington University Memory Diagnostic Center (MDC) in St. Louis, Missouri, sees approximately 4,000 patients with memory and thinking concerns annually and has been using blood biomarkers to assess for Alzheimer disease (AD) pathology and to determine eligibility for anti‐amyloid treatments.
